RHHBYRoche Holding AG
The schedule
- Tue15Sep
Presentation of critical clinical trial data for next-generation oncology and immunology assets at major medical congresses (e.g., ESMO).
- Thu15Oct
Release of third-quarter 2026 sales performance across the pharmaceutical and diagnostics divisions.
- Sat14Nov
Evaluation of regulatory shifts and reimbursement negotiations affecting mature and high-priced biologics portfolios across major global markets.
- Thu4Feb
Announcement of full-year 2026 financial results and initial corporate guidance for 2027.
- Mon1Mar
Market reassessment of long-term revenue erosion curves as major legacy products approach late-decade patent expirations and face biosimilar entrants.
Past
- Sat25Jul
Actual outcome: Bull · $58.27 at outcome
Price reached or exceeded bull target ($55.00) at outcome date.
H1 2026 earnings and the updated 2026 guidance will test whether Roche can reaccelerate from slightly negative headline revenue growth while sustaining the margin gains seen in 2025. A clean print with stable core oncology and immunology sales could justify a move toward $55.00, while any guidance cut tied to biosimilar pressure or slower diagnostics demand could pull the ADR back toward $55.00.